After the synthesis of desoxycorticosterone (DOC), it became apparent that this corticosteroid, the physiological effects of which are concerned primarily with sodium and potassium metabolism, can produce a state of hypertension both in animals and in man (1, 2) . The induced hypertension is dependent upon the administration of adequate amounts of dietary sodium, whereas the hypertensive state, produced by administration of glucocorticoids such as cortisone, differs in that it is independent of the dietary sodium content (3) .
More recently, following the chemical and biological characterization of the mineralocorticoid hormone, aldosterone (4), a disease state associated with primary hypersecretion of this hormone has been described in man (5) . Aldosterone produces effects on sodium and potassium metabolism similar to those of desoxycorticosterone, and the clinical syndrome of primary aldosteronism resembles the disease state produced by chronic administration of DOC to dogs (6) . Arterial hypertension has been a consistent finding in patients with primary hyperaldosteronism.
A number of other observations have suggested a relationship between the dietary sodium intake and the blood pressure level of patients with primary (benign essential) hypertension. The beneficial effects of sodium deprivation, and of various natriuretic agents in certain patients with hypertension, is well known. In addition, other studies have suggested that abnormalities of intracellular sodium and potassium content may occur in patients with arterial hypertension (7) . Genest, Koiw, Nowaczynski and Lebouef (8) ported that the urinary excretion of aldosterone was significantly increased in 55 per cent of their patients with hypertension of diverse etiologies. The increased levels of urinary aldosterone were not correlated with any abnormality of sodium or potassium metabolism, nor did the increased values appear to be specifically associated with any particular type of hypertensive disease.
It has been recognized that the measurement of urinary excretion of unchanged hormone may not accurately reflect significant changes in adrenal secretion of aldosterone. During the past several years a method has been devised which provides an estimate of the amount of aldosterone which is actually produced by the adrenal glands (9) . The technique involves the injection of a trace amount of tritiated aldosterone and the determination of the specific activity of a urinary metabolite of aldosterone in the subsequent 24 hour urine. The difference between the specific activity of the injected hormone and that of the urinary metabolite is considered to be a measure of the endogenous production of aldosterone and, as such, permits the estimation of the daily secretion rate. In the present report, this technique has been applied to the study of patients with arterial hypertension. In the course of these studies an effort has been made to correlate abnormalities in aldosterone secretion with abnormalities in sodium and potassium metabolism and, when possible, with changes in the morbid anatomy of the adrenal gland itself. The results have been compared with values obtained from normal subjects and from patients with known primary aldosteronism.
METHODS AND MATERIALS
Patient selection. All of the patients studied were hospitalized. A complete history and physical examina-tion, routine laboratory tests, plasma and urinary electrolytes, intravenous pyelography and measurement of catecholamine excretion were obtained in all patients. None of the patients included in the group had evidence of congestive heart failure. Frequently, the dietary intake of sodium was stabilized by means of a constant diet prepared by the metabolic ward kitchen, and serial control observations were then made while the patients were on the metabolic ward. These detailed studies will be reported at a later date. Some of the patients were hospitalized at the Goldwater Memorial Hospital, Columbia Division. All of the latter group had been in the hospital for considerable periods of time, and in several instances, daily blood pressure measurements for several years, as well as frequent determinations of plasma and urinary electrolytes, were available.
Classification of hypertensive patienits. After efforts to exclude primary renal or adrenal disease the remaining hypertensive group selected for study was subdivided. The patients with elevated blood pressures but with no evidence of renal insufficiency or of arteritis were classified as "primary hypertension" (often called, "benign essential" hypertension). The patients with high blood pressure and evidence of renal or retinal complications were classified as "advanced hypertension" or "primary hypertension with complications." The criterion for renal complications was the presence of either proteinuria or a blood urea nitrogen greater than 30 mg per 100 ml or both. Retinal complications refer to the presence of retinal hemorrhages (Grade III retinopathy according to the standard classification). Patients with unequivocal papilledema were classified as the accelerated form or "malignant" hypertension. It was recognized that this classification, although useful, was arbitrary, and that diverse etiologies could exist within these categories. For comparative purposes a group of patients with primary aldosteronism was also studied. Diagnosis in these patients was made on the basis of 1) hypokalemic alkalosis, 2) hypertension, and 3) the finding of an adrenal tumor at operation or at postmortem.
The metabolic ward techniques and the methods used for measurement of plasma and urinary electrolytes have been reported previously (10 Urine was collected for 24 hours after the injection of tritiated aldosterone and hydrolyzed with a-glucuronidase at pH 5.0 for 3 days at 370 C. An extract of the hydrolyzed urine was prepared with ethyl acetate. The tetrahydro-metabolite of aldosterone was isolated from the extract by paper chromatography, and acetylated with C14-labeled acetic anhydride of known specific activity. The triacetate of the metabolite then was chromatographed first on paper and next on a partition column. The H3/C14 ratios in the fractions from the partition column were determined by liquid scintillation counting with a Packard Tri-Carb scintillation counter using the discriminator ratio method of Okita, Kabara, Richardson and LeRoy (12) . Constancy of the ratios in the area of the tritium peak is indicative of radiochemical purity. The aldosterone secretion rate in micrograms per day can be shown to equal counts per minute of aldosterone injected specific activity of the metabolite in 24 hour urine' (counts per minute per microgram) H3/C14 times the specific activity of the C`4-acetic anhydride equals the specific activity of the aldosterone metabolite. It is evident that the H3/C14 ratio is a measure of the specific activity of the metabolite. This technique has been previously outlined (9) and will be described in detail in a manuscript which is in preparation.
Plait of study. Because aldosterone secretion varies considerably with the dietary sodium intake (9), an effort was made to stabilize the dietary sodium content for at least 5 days prior to study. With this precaution and in the absence of any demonstrable renal or adrenal insufficiency it was felt that the 24 hour urinary sodium level represented a reasonably good index of sodium metabolism at the time the aldosterone production was measured. In 17 subjects in whom a metabolic balance was not feasible the urinary sodium content was checked for several days before and after the administration of aldosterone. If these values were not grossly reduced (below 20 mEq per day), if the patients exhibited no other signs of fluid retentioni, and if there was no history of recent sodium deprivation, a state of sodium retention was considered unlikely. However, in most (20 of 27) of these patients a complete metabolic balance was carried out. In no instance did the patients receive diuretic agents for at least 3 weeks prior to study.
RESULTS
The results are summarized in Table I and in Figure 1 .
Normal subjects. In Figure 1 the results obtained in eight normal subjects on unselected diets are presented graphically. The aldosterone secretion rate ranged from 150 to 330 ,ug per day in these eight subjects. The corresponding 24 The urinary sodium content of the corresponding 24 hour urine collection is also shown. There is no evident hypersecretion of aldosterone in primary hypertension. In malignant hypertension marked hypersecretion of aldosterone was found and the values were often higher than those encountered in patients with primary aldosteronism. The patients with malignant hypertension resembled those with primary aldosteronism in that the hypersecretion was not associated with grossly reduced sodium excretion.
hibited hypokalemia and all but one had an elevated plasma bicarbonate level. All of these patients had adrenal adenomas. In Patient 11 As in the patients with primary aldosteronism, the increased aldosterone production was observed in the presence of relatively high urine sodium levels ( Figure 1 ). The plasma bicarbonate levels were 28 mEq per L or higher in four of these patients, and in all but one plasma potassium levels were less than 4 mEq per L. With one exception (Patient 19) the increased aldosterone secretory rates were found in the patients with relatively high plasma bicarbonate levels. In five of the eight patients in this group the blood urea nitrogen exceeded 30 mg per 100 ml. However, the elevated aldosterone production did not appear to be constantly associated with this nitrogen retention. Patient 20 was subjected to laparotomy, and, when no tumor was found, a left adrenalectomy was carried out. The gland was grossly normal but microscopically revealed some nodularity and focal hyperplasia. It is of interest that following this procedure there was a sustained (9 months' observation) fall in blood pressure to levels of 170/110 and complete clearing of retinal hemorrhages. After the unilateral adrenalectomy the aldosterone secretion rate was also markedly reduced from 1,170 ug per day to a value within the normal range of 352 ,ug per day. The sequence of events raised the possibility that hypersecretion of aldosterone might have been a factor in accelerating this patient's hypertensive disease.
Malignant hypertension (Patients 24-38). Fifteen patients with malignant hypertension characterized by papilledema were studied. The known duration of the hypertension in this group ranged from 2 months to 20 years. However, the duration of the papilledema in these cases is difficult to determine. In most instances, it appeared to be a relatively recent development as the disease state progressed from the benign to the so-called accelerated form.
The The markedly increased aldosterone secretion in this group of patients was found, as in the patients with Conn's syndrome, to occur in the presence of relatively high urinary sodium levels and was, therefore, clearly not associated with a state of progressive sodium retention. Although the urinary Na levels were never grossly reduced (range, 25 to 113 mEq per day), they were somewhat lower than those in the other patients (see Figure  1 ). There was no evidence of significant positive sodium balance in any of these patients and the lowered excretions were the result of lower intake. The increased aldosterone secretion appears to be far in excess of what one would normally find in association with such levels of urinary sodium excretion.
Relation of aldosterone secretion to blood pressure level. No correlation was evident between the degree of elevation of blood pressure and the degree of elevation in the aldosterone secretory rate in this series of patients. Many of the patients with primary hypertension manifested blood pressure elevations which were as high or higher than those observed in the patients with primary hypertension with complications, or in the patients with malignant hypertension.
Relation of aldosterone secretion rate to renal insufficiency. The patients with advanced or with malignant hypertension often exhibited significant nitrogen retention (13 of 23 with blood urea ni-trogen above 30 mg per 100 ml). Yet, it is difficult to relate the increased aldosterone secretion specifically to this renal failure since a number of the patients (7 of 23) had elevated aldosterone secretion rates with a normal blood urea nitrogen.
It has been shown that patients with sodiumlosing renal disease may excrete large amounts of aldosterone. Presumably this is a secondary mechanism in an attempt to conserve sodium. Also, these patients may continue to excrete increased amounts of aldosterone long after sodium repletion, a phenomenon which has been termed "secondary primary aldosteronism" (13 It is important to emphasize that, conceivably, as a consequence of severe renal disease the method as employed might yield an apparently high secretory rate in the absence of true hypersecretion of aldosterone. A basic requirement which must be fulfilled, if the isotope dilution technique used in this study is to measure the true secretion rate, is that the reactions involved in the conversion of radioactive hormone to radioactive metabolite and also in excretion of the radioactive metabolite into the urine must have gone to completion within the period during which the urine is collected. In other words, regardless of the other metabolites to which the injected labeled hormone may be converted, all of the isotopically labeled tetrahydrometabolite which is to be formed must have been formed and excreted within the collection period. If additional amounts of radioactive metabolite were to be excreted into subsequent urine collections, then the conditions necessary for determination of the secretion rate by isotope dilution would not exist and the value of the secretory rate derived from such an incomplete collection would be artificially high.
It has already been shown (14) that the fraction of radioactivity originating from injected C14-cortisol that appears in urine and, to a much lesser extent, the rate at which it appears in the urine, are related to the clearance of creatinine. Normal individuals with clearances of about 125 ml per minute excreted about 80 per cent of C14 in the first day's urine, whereas patients with kidney disease and creatinine clearances of 42 to 55 ml per minute excreted about 50 per cent in the first day, and patients with creatinine clearances of 5 to 9 ml per minute excreted only about 3 per cent in the first 24 hours. Perhaps more importantly, in all of the subjects, very little additional radioactivity appeared on the second and third days.
The condition set forth above does not require that a certain percentage of injected radioactivity must appear in the urine. If the assumption is made that the injected labeled molecules have the same fate as the endogenously produced hormone, then if only a small fraction of injected hormone is converted to radioactive metabolite, a similar small fraction of the endogenous hormone undergoes the same fate. It is only necessary that the collection period be long enough to permiiit complete formation and then complete excretion of all the radioactive metabolite which is to be excreted.
Analysis of the dlata presented in Table II reveals no consistent relationship between the blood urea nitrogen and the aldosterone secretion rate. In Table II groups; the former ranging from 7.9 to 14.3 per cent; the latter, from 3.4 to 11.5 per cent. Patient 37 with a blood urea nitrogen of 78 mg per 100 ml had a secretory rate of 10,000 ,ug per day, whereas Patient 29 with a blood urea nitrogen of 71 mg per 100 ml had a secretory rate of only 860
Mug per day.
Of the patients in this group an effort was made only once to determine whether radioactivity was still being excreted after the first day. Patient 32 who excreted 11.5 per cent of the injected tritium on the first day (secretory rate = 2,730 ug) excreted no detectable radioactive metabolite on the second day. Thus, in this single study, at least, the observed high secretion rate appears to be unrelated to renal failure, because all of the radioactive metabolite destined for excretion appeared within the first 24 hours. While this requirement has not actually been demonstrated in the other subjects with renal failure, the fact that these subjects often excreted about as much isotope as did the normal controls, and the fact that high secretion rates did not always correlate with renal failure, tend to indicate that the observed increases in aldosterone secretion are not related to kidney disease but rather to a truly increased adrenal production.
Because an abnormally prolonged excretion of isotopically labeled metabolite in renal disease would produce artificially high estimates of the 24 hour secretory rate, another group of ten patients has been studied in which the urinary collection periods were extended to two or three days, and the specific activity of labeled metabolite was determined for each of the days of collection. These data are summarized in Table III and in Figure 2 . Included in this group are three pregnant women in the third trimester, four patients with renal diseases other than malignant hypertension, one patient with uncomplicated hypertension (normal renal function) and three patients with malignant hypertension.
Since accurate quantitation of the amount of radioactivity in the metabolite is difficult, its specific activity, derived from the ratio of H3 to C14 in the triacetate of the metabolite, was determined instead. If the major portion of labeled metabolite is excreted in the first 24 hours, the H3/C14 ratio for the first day should be much higher than that for subsequent days. The average secretion per day over a two or three day period was calculated from the average H3/C14 ratio over the given period. When the average secretion rate was the same as the secretion rate determined for In the application of this method to the study of diseases associated with renal insufficiency, such as malignant hypertension, the critical question is whether delayed excretion of the isotope causes overestimation of the 24 hour secretory rate beyond the 10 per cent error normally encountered. The data presented in Table III 26 .5 per cent (or, more properly, by the 16.5 per cent value in excess of the normal error). However, in Imlost instances, the error is less. The 26.5 per cent figure was obtained in a patient with a blood urea nitrogen of 104 mg per 100 ml (Patient 10). Thus, the rate of excretion of the labeled metabolite by two subjects with overt renal insufficiency (Patients 6 and 7) did not differ significantly from patients with normal renal function. Of special interest is the finding that in two patients with malignant hypertension and azotemia (Patients 6 and 8), both tested twice, the percentages of labeled metabolite excreted in the first day were 89.8, 87.3, 77 and 74 per cent.
One comatose patient with malignant hypertension and terminal urenmia, who died the day after the last collection, has been included. This patient was obviously moribund. Unlike all others, the specific activity of the metabolite did not fall between the first and second days and fell by only 50 per cent in three days. The minimum estimated secretory rate was 6,000, but this result is obviously invalid because no evidence for completeness of excretion of metabolite could be obtained before death of the patient. The number of counts excreted was small and constituted a trace of the injected dose. In contrast, in the one patient of the present series of malignant hypertensive subjects with a similarly high estimated secretory rate of 10,000 ,ug (Patient 37, Table II) both the amount and the percentage of labeled metabolite excreted were similar to that of normal subjects and were considerably higher than those observed in Patient 11 of Table III. The possible error associated with this estimated 10,000 ug production value was not determined, but from the experience summarized in Table III it seems likely that the corrected value would be considerably elevated above the normal range.
The experience summarized in Table III and in Figure 2 illustrates that the renal excretion of labeled tetrahydroaldosterone is inversely related to the excretion of urea. The data indicate that a secretion rate value in patients with azotemia may need to be corrected by as much as about 30 per cent. The data suggest that a correction factor based on the degree of azotemia should be applied to each of the secretion rates given in Correlation of findings withi miorphological changes in the adrenal tissuie. In seven of the patients with malignant hypertension reported in this study, complete postmortem examination has been made. No tuimor was found in the adrenals of any of these patients, but in four of the seven the adrenal glands were significantly above the upper limits of normal in weight. In all seven subjects the glands exhibited areas of focal hyperplasia and nodularity, especially in the region of the glomerulosa zone. In additioni, there was focal increase in cellular activity and increased lipid deposits in focal cellular areas. Pathological findings in these cases, as well as in two other surgical specimens. will be the subject of a separate report (16 In the patients reported here hypersecretion of aldosterone was often found in association with demonstrable renal insufficiency. One cannot deny that sodium-losing renal disease could lead to secondary hypersecretion of aldosterone in patients with advancing hypertensive disease. However, as pointed out above, the data obtained thus far do not tend to suggest the operation of such a mechanism. (Most of the patients conserved sodium normally.) Further study of patients with other forms of renal disease may be necessary to determine a possible relationship between aldosterone secretion and renal insufficiency. It should be restated here that the technique employed for estimation of adrenal secretion may be affected by renal insufficiency, but the error caused by delayed excretion has not been of sufficient magnitude to invalidate the results.
In general, the hypersecretion of aldosterone was more impressive in the seriously ill patients (10 of the 15 patients with malignant hypertension are now deceased). However, whether the aldosterone hypersecretion is a cause or a result of the severe disease is not clear. Hypersecretion of aldosterone has not been noted in association with various other severe illnesses (17) , but here too, further studies are necessary, especially in patients with other forms of arteritis.
Prior to the present study, the association of potassium depletion and alkalosis with severe hypertension has been noted. Wyngaarden, Keitel and Isselbacher (18) reported the case of a 46 year old man with malignant hypertension and severe alkalosis whose adrenal glands were grossly normal at postmortem. Two other cases of potassium depletion associated with malignant hypertension and high aldosterone excretion have been reported (19, 20) . In both, the authors considered that the observed aldosteronism might have been secondary to renal damage. Both of these patients succumbed without being helped by bilateral adrenalectomy, and here too, the adrenal glands were not grossly abnormal.
About 35 cases of primary aldosteronism have now been reported (17) . About 28 of these have been shown to be associated with an adrenal adenoma, and two others were associated with adrenal carcinoma (21, 22) . Hypertension of varying degree was present in all of the cases, but in only one of the cases associated with an adenoma was the hypertension malignant (23) . This patient died without operation. In marked contrast, and of special interest in relation to the present study, is the fact that in five of the six reported cases (15, (24) (25) (26) (27) (28) of primary aldosteronism associated with bilateral adrenal cortical hyperplasia, the syndrome of malignant hypertension with papilledema was present. In all but one of these six patients subtotal adrenalectomy was carried out and was followed by improvement. The fact that the syndrome of malignant hypertension was so often found in these patients labeled "primary aldosteronism due to bilateral adrenal hyperplasia." illustrates again a fundamental difficulty in properly classifying these diseases. Obviously, these reported cases might well have been more appropriately classified as examples of "malignant hypertension" rather than of "primary aldosteronism."
The finding of an adrenal adenoma at least suggests a primary adrenal disease. On the other hand, the occurrence of bilateral adrenal hyperplasia is in keeping with secondary rather than with primary adrenal disease. In other words, the two diseases may be of entirely different origin. Also, they appear to be associated with different clinical pictures-bilateral adrenal hyperfunction being characteristically associated with malignant hypertension. However, as yet, no biochemical differences are apparent which might aid one in distinguishing the disease state of bilateral hyperplasia from that of an adrenal adenoma. Four of the cases of bilateral hyperplasia occurred at a young age (ages 9, 10, 13 and 17) and one other case (15) exhibited an abnormal glucocorticoid response to ACTH. One of our patients (no. 20) resembles the patient reported by Holten and Petersen (25) in that unilateral adrenalectomy in both was followed by a fall in aldosterone and striking clinical improvement. In both patients the excised adrenal gland was histologically unremarkable. However, it is also possible that aldosterone hypersecretion remits spontaneously, and one of our patients (no. 34 If aldosterone is important in the pathogenesis of malignant hypertension, one might ask whether beneficial effects are to be expected from bilateral adrenalectomy. Unfortunately, this question cannot be categorically answered since results of adrenalectomy have been variable, and since many patients with malignant hypertension have been excluded from surgery because of attendant renal insufficiency. One patient in our series (no. 25) was subjected to bilateral adrenalectomy, but following the second operation terminal uremia developed. Two similar experiences have been reported (19, 20) . It is possible that a more satisfactory answer can be obtained when patients are operated on earlier in the malignant phase. However, in this regard it should be remembered that in animals, after a certain stage, hypertension progresses when desoxycorticosterone is no longer administered ("metacorticoid" hypertension) (29) . Another, perhaps more promising, approach to the problem involves the administration of aldosterone inhibitors. These studies are currently under way in our laboratory.
The findings reported here perhaps confirm in part the work of Genest and associates (8) who reported increased urinary excretion of aldosterone in some patients with malignant hypertension. However, these workers also found increased aldosterone excretion in milder forms of hypertension, and this latter finding is at variance with our data.
SUM MARY
A technique of isotope dilution which involves the injection of a trace dose of tritiated aldosterone and the determination of the specific activity of labeled tetrahydroaldosterone in the subsequent 24 hour urine has been applied to the study of patients with hypertensive vascular disease. The technique obviates a difficulty inherent in previous studies which have been based on measurement of the small fraction of aldosterone excreted unchanged in urine.
In eight patients with benign essential hypertension, the adrenal secretion rate of aldosterone was found to be within the normal limits (180 to 330 ,ug per day). The values were similar to those obtained in eight normal subjects maintained on comparable normal intakes of sodium ion.
The secretion rate of aldosterone was also within the normal range in two patients with hypertension associated with unilateral renal disease.
Five patients with proven primary aldosteronism due to adrenal adenoma (Conn's syndrome) exhibited significantly increased secretory rates of from 510 to 1,690 ,ug per day.
In three of eight advanced hypertensive patients studied, and in all but one of 15 patients with malignant hypertension, the adrenal secretion rate of aldosterone was significantly elevated. The abnormal values ranged upwards from 510 ,ug per day in these patients. The patients with malignant hypertension resembled those with primary aldosteronism in that the hypersecretion was not associated with grossly reduced urinary sodium excretion. With unexpected frequency, the patients with malignant hypertension also exhibited a tendency to hypokalemia and/or an elevated plasma bicarbonate level, even in the presence of renal failure.
Delayed excretion of the labeled metabolite can be related to the degree of nitrogen retention present and may lead to artificially high estimates of the 24 hour secretion rate. Nevertheless, in the experience to date the error produced by excretory failure does not appear to be of sufficient magnitude to invalidate results based on 24-hour urine collections.
The results provide no indication that aldosterone hypersecretion participates in the pathogenesis of primary (benign) hypertension.
The data obtained on the patients studied establish that the syndrome of malignant hypertension is usually associated with hypersecretion of aldosterone. In addition to the differences in the clinical picture between patients with malignant hypertension and those with Conn's syndrome, the hypersecretion of aldosterone may differ in its origin. In malignant hypertension it seems to be due to bilateral adrenal hyperfunction rather than to an adrenal adenoma.
Hypersecretion of aldosterone in the syndrome of malignant hypertension may prove to be a secondary or concomitant phenomenon. However, the results presented here make it reasonable to consider the possibility that hypersecretion of aldosterone plays a causal role in malignant hypertension.
